PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-168.99%
Negative EBIT growth while Healthcare median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-230.56%
Negative operating income growth while Healthcare median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-176.90%
Negative net income growth while Healthcare median is 0.00%. Seth Klarman would investigate factors dragging net income down.
89.62%
EPS growth of 89.62% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
89.62%
Diluted EPS growth of 89.62% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
2567.99%
Share change of 2567.99% while Healthcare median is zero. Walter Schloss would see if the modest difference matters long-term.
2567.99%
Diluted share change of 2567.99% while Healthcare median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
-298628.16%
Negative OCF growth while Healthcare median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-217028.56%
Negative FCF growth while Healthcare median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-67594.88%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-60146.79%
Negative 5Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-86002.39%
Negative 3Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-51844.29%
Negative 10Y net income/share CAGR vs. Healthcare median of 7.14%. Seth Klarman might see a fundamental problem if peers maintain growth.
-93706.66%
Negative 5Y CAGR while Healthcare median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-45701.99%
Negative 3Y CAGR while Healthcare median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
3346.07%
Equity/share CAGR of 3346.07% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
1899.20%
5Y equity/share CAGR of 1899.20% while Healthcare median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
720.41%
3Y equity/share CAGR of 720.41% while Healthcare median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
104.51%
Asset growth of 104.51% while Healthcare median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
-98.43%
Negative BV/share change while Healthcare median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
92.16%
Debt growth of 92.16% while Healthcare median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
-30.73%
R&D dropping while Healthcare median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
522.30%
SG&A growth of 522.30% while Healthcare median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.